Kura Oncology announces preclinical data for KO-2806 to be presented at AACR

Kura Oncology (KURA) announced that an abstract containing preclinical data for KO-2806, the Company’s next-generation farnesyl transferase inhibitor, in combination with cabozantinib, a tyrosine kinase inhibitor, in clear cell renal cell carcinoma, has been accepted for an oral presentation at the upcoming American Association for Cancer Research Annual Meeting in Chicago, IL on April 29, 2025. “The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year’s AACR Annual Meeting, add to the growing body of data demonstrating the potential of FTIs as companion therapeutic agents to augment the antitumor activities of various targeted therapies and to overcome resistance in combination,” said Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology. “We continue to make good progress in our FIT-001 trial evaluating KO-2806 in solid tumor indications where there is unmet medical need, and we look forward to presenting the first clinical data for KO-2806 as monotherapy and in combination with cabozantinib for the treatment of RCC later this year.”